Centessa Pharmaceuticals Analyst Ratings
Centessa Pharmaceuticals Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
11/15/2023 | 80.33% | Jefferies | $4 → $11 | Upgrades | Hold → Buy |
10/26/2023 | 31.15% | Morgan Stanley | $4 → $8 | Upgrades | Underweight → Equal-Weight |
08/15/2023 | 80.33% | SVB Securities | $6 → $11 | Maintains | Outperform |
08/15/2023 | 63.93% | Guggenheim | $9 → $10 | Maintains | Buy |
08/15/2023 | -18.03% | Goldman Sachs | $4.5 → $5 | Maintains | Neutral |
07/25/2023 | 145.9% | BMO Capital | $11 → $15 | Maintains | Outperform |
06/21/2023 | — | Evercore ISI Group | Initiates Coverage On | → Outperform | |
06/12/2023 | 47.54% | Guggenheim | → $9 | Initiates Coverage On | → Buy |
05/15/2023 | -26.23% | Goldman Sachs | $4 → $4.5 | Maintains | Neutral |
03/17/2023 | -1.64% | SVB Leerink | → $6 | Initiates Coverage On | → Outperform |
01/24/2023 | -34.43% | Morgan Stanley | $5 → $4 | Maintains | Underweight |
08/12/2022 | -18.03% | Morgan Stanley | $10 → $5 | Downgrades | Overweight → Underweight |
08/11/2022 | 80.33% | BMO Capital | $19 → $11 | Maintains | Outperform |
08/11/2022 | -34.43% | Goldman Sachs | $5 → $4 | Maintains | Neutral |
07/15/2022 | 63.93% | Morgan Stanley | $15 → $10 | Maintains | Overweight |
06/17/2022 | 211.48% | BMO Capital | → $19 | Initiates Coverage On | → Outperform |
05/24/2022 | 145.9% | Morgan Stanley | $19 → $15 | Maintains | Overweight |
05/24/2022 | 31.15% | Goldman Sachs | $12 → $8 | Maintains | Neutral |
04/05/2022 | 211.48% | Morgan Stanley | $20 → $19 | Maintains | Overweight |
06/23/2021 | 506.56% | Morgan Stanley | → $37 | Initiates Coverage On | → Overweight |
06/22/2021 | 588.52% | Goldman Sachs | → $42 | Initiates Coverage On | → Buy |
06/22/2021 | 506.56% | Morgan Stanley | → $37 | Initiates Coverage On | → Overweight |
06/22/2021 | 473.77% | Jefferies | → $35 | Initiates Coverage On | → Buy |
日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
---|---|---|---|---|---|
11/15/2023 | 80.33% | 杰富瑞集团 | 4 美元 → 11 美元 | 升级 | 持有 → 买入 |
2023 年 10 月 26 日 | 31.15% | 摩根士丹利 | 4 美元 → 8 美元 | 升级 | 体重不足 → 重量相等 |
08/15/2023 | 80.33% | SVB 证券 | 6 美元 → 11 美元 | 维护 | 跑赢大盘 |
08/15/2023 | 63.93% | 古根海姆 | 9 美元 → 10 美元 | 维护 | 买 |
08/15/2023 | -18.03% | 高盛 | 4.5 美元 → 5 美元 | 维护 | 中立 |
07/25/2023 | 145.9% | BMO Capital | 11 美元 → 15 美元 | 维护 | 跑赢大盘 |
06/21/2023 | — | Evercore ISI 集团 | 启动覆盖范围开启 | → 跑赢大盘 | |
06/12/2023 | 47.54% | 古根海姆 | → 9 美元 | 启动覆盖范围开启 | → 购买 |
05/15/2023 | -26.23% | 高盛 | 4 美元 → 4.5 美元 | 维护 | 中立 |
03/17/2023 | -1.64% | SVB Leerink | → 6 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
01/24/2023 | -34.43% | 摩根士丹利 | 5 美元 → 4 美元 | 维护 | 体重不足 |
2022 年 12 月 8 日 | -18.03% | 摩根士丹利 | 10 美元 → 5 美元 | 降级 | 超重 → 体重不足 |
08/11/2022 | 80.33% | BMO Capital | 19 美元 → 11 美元 | 维护 | 跑赢大盘 |
08/11/2022 | -34.43% | 高盛 | 5 美元 → 4 美元 | 维护 | 中立 |
07/15/2022 | 63.93% | 摩根士丹利 | 15 美元 → 10 美元 | 维护 | 超重 |
2022 年 6 月 17 日 | 211.48% | BMO Capital | → 19 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
2022 年 5 月 24 日 | 145.9% | 摩根士丹利 | 19 美元 → 15 美元 | 维护 | 超重 |
2022 年 5 月 24 日 | 31.15% | 高盛 | 12 美元 → 8 美元 | 维护 | 中立 |
2022 年 5 月 4 日 | 211.48% | 摩根士丹利 | 20 美元 → 19 美元 | 维护 | 超重 |
06/23/2021 | 506.56% | 摩根士丹利 | → 37 美元 | 启动覆盖范围开启 | → 超重 |
06/22/2021 | 588.52% | 高盛 | → 42 美元 | 启动覆盖范围开启 | → 购买 |
06/22/2021 | 506.56% | 摩根士丹利 | → 37 美元 | 启动覆盖范围开启 | → 超重 |
06/22/2021 | 473.77% | 杰富瑞集团 | → 35 美元 | 启动覆盖范围开启 | → 购买 |
What is the target price for Centessa Pharmaceuticals (CNTA)?
Centessa Pharmicals(CNTA)的目标价格是多少?
The latest price target for Centessa Pharmaceuticals (NASDAQ: CNTA) was reported by Jefferies on November 15, 2023. The analyst firm set a price target for $11.00 expecting CNTA to rise to within 12 months (a possible 80.33% upside). 11 analyst firms have reported ratings in the last year.
杰富瑞集团于2023年11月15日公布了Centessa Pharmicals(纳斯达克股票代码:CNTA)的最新目标股价。该分析公司将目标股价定为11.00美元,预计CNTA将在12个月内升至12个月内(可能上涨80.33%)。去年有11家分析公司公布了评级。
What is the most recent analyst rating for Centessa Pharmaceuticals (CNTA)?
Centessa Pharmicals(CNTA)的最新分析师评级是多少?
The latest analyst rating for Centessa Pharmaceuticals (NASDAQ: CNTA) was provided by Jefferies, and Centessa Pharmaceuticals upgraded their buy rating.
杰富瑞集团提供了Centessa Pharmicals(纳斯达克股票代码:CNTA)的最新分析师评级,Centessa Pharmicals上调了买入评级。
When is the next analyst rating going to be posted or updated for Centessa Pharmaceuticals (CNTA)?
Centessa Pharmicals(CNTA)的下一个分析师评级何时公布或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Centessa Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Centessa Pharmaceuticals was filed on November 15, 2023 so you should expect the next rating to be made available sometime around November 15, 2024.
分析师在进行了广泛的研究后得出了股票评级,其中包括浏览公开财务报表,与Centessa Pharmicals的高管和客户交谈,以及听取财报电话会议。大多数分析师每三个月做一次这样的评级,因此每家公司每年应该获得4次评级。Centessa Pharmicals的最新评级是在2023年11月15日公布的,因此您应该预计下一个评级将在2024年11月15日左右公布。
Is the Analyst Rating Centessa Pharmaceuticals (CNTA) correct?
分析师对Centessa Pharmicals(CNTA)的评级正确吗?
While ratings are subjective and will change, the latest Centessa Pharmaceuticals (CNTA) rating was a upgraded with a price target of $4.00 to $11.00. The current price Centessa Pharmaceuticals (CNTA) is trading at is $6.10, which is within the analyst's predicted range.
尽管评级是主观的,并且会发生变化,但最新的Centessa Pharmicals(CNTA)评级已上调,目标股价为4.00美元,至11.00美元。Centessa Pharmicals(CNTA)目前的交易价格为6.10美元,在分析师的预测区间内。